AR092325A1 - Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit - Google Patents

Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit

Info

Publication number
AR092325A1
AR092325A1 ARP130101868A ARP130101868A AR092325A1 AR 092325 A1 AR092325 A1 AR 092325A1 AR P130101868 A ARP130101868 A AR P130101868A AR P130101868 A ARP130101868 A AR P130101868A AR 092325 A1 AR092325 A1 AR 092325A1
Authority
AR
Argentina
Prior art keywords
seq
kit
formulations containing
containing anti
dll4 antibodies
Prior art date
Application number
ARP130101868A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092325(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR092325A1 publication Critical patent/AR092325A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Reivindicación 1: Una formulación farmacéutica que comprende: (i) un anticuerpo que se une específicamente a ligando tipo d humano 4 (Dll4); (ii) un amortiguador a pH de 6,0 ± 0,5; (iii) un cosolvente orgánico; y (iv) dos estabilizadores térmicos. Reivindicación 2: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde el anticuerpo comprende una HCDR1 de SEC ID Nº 2, una HCDR2 de SEC ID Nº 3, una HCDR3 de SEC ID Nº 4, una LCDR1 de SEC ID Nº 6, una LCDR2 de SEC ID Nº 7 y una LCDR3 de SEC ID Nº 8. Reivindicación 3: La formulación farmacéutica de acuerdo con la reivindicación 1 o la reivindicación 2, en donde el anticuerpo comprende una HCVD de SEC ID Nº 1 y una LCVD de SEC ID Nº 5.
ARP130101868A 2012-05-31 2013-05-29 Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit AR092325A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
AR092325A1 true AR092325A1 (es) 2015-04-15

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101868A AR092325A1 (es) 2012-05-31 2013-05-29 Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit

Country Status (29)

Country Link
US (1) US9675692B2 (es)
EP (1) EP2854849B1 (es)
JP (1) JP6144758B2 (es)
KR (1) KR20150033615A (es)
CN (1) CN104349791A (es)
AR (1) AR092325A1 (es)
AU (1) AU2013267301B2 (es)
BR (1) BR112014028997A2 (es)
CA (1) CA2872275C (es)
CL (1) CL2014003237A1 (es)
CO (1) CO7151478A2 (es)
DK (1) DK2854849T3 (es)
EA (1) EA029779B1 (es)
ES (1) ES2668900T3 (es)
HK (1) HK1207305A1 (es)
IL (1) IL235468A0 (es)
LT (1) LT2854849T (es)
MA (1) MA37645B1 (es)
MX (1) MX357146B (es)
NO (1) NO2887943T3 (es)
NZ (1) NZ702288A (es)
PH (1) PH12014502429B1 (es)
PL (1) PL2854849T3 (es)
PT (1) PT2854849T (es)
SG (1) SG11201407171XA (es)
SI (1) SI2854849T1 (es)
TW (1) TWI609696B (es)
UY (1) UY34842A (es)
WO (1) WO2013181486A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2488204B1 (en) 2009-10-16 2016-04-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
RS63965B1 (sr) 2011-09-23 2023-03-31 Mereo Biopharma 5 Inc Vegf/dll4 vеzujući agensi i njihova upotreba
JP6827415B2 (ja) 2014-10-31 2021-02-10 メレオ バイオファーマ 5 インコーポレイテッド 疾患の処置のための併用療法
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
JP7570234B2 (ja) * 2018-04-16 2024-10-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 熱安定性を改善するためのタンパク質製剤のための添加剤
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
WO2022010988A1 (en) * 2020-07-08 2022-01-13 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ctla-4 antibodies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
IL133220A0 (en) 1997-06-13 2001-03-19 Genentech Inc Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
JP3792698B2 (ja) 2002-02-14 2006-07-05 中外製薬株式会社 抗体含有溶液製剤
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SI2586459T1 (sl) 2005-03-25 2017-10-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonistov VEGF
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
AU2007261536B2 (en) 2006-06-16 2012-02-16 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
WO2008049897A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
EP2488204B1 (en) * 2009-10-16 2016-04-06 Oncomed Pharmaceuticals, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
MX2012005863A (es) 2009-11-20 2013-01-18 Centro Inmunologia Molecular Formulaciones de anticuerpos.
CA2791631A1 (en) * 2010-03-02 2011-09-09 Abbvie Inc. Therapeutic dll4 binding proteins
EA028945B1 (ru) * 2010-10-06 2018-01-31 Ридженерон Фармасьютикалз, Инк. СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К АЛЬФА РЕЦЕПТОРУ ЧЕЛОВЕЧЕСКОГО ИНТЕРЛЕЙКИНА-4 (hIL-4Rα)

Also Published As

Publication number Publication date
AU2013267301A1 (en) 2014-12-18
DK2854849T3 (en) 2018-04-30
ES2668900T3 (es) 2018-05-23
CL2014003237A1 (es) 2015-07-10
HK1207305A1 (en) 2016-01-29
SI2854849T1 (en) 2018-05-31
PL2854849T3 (pl) 2018-07-31
EP2854849B1 (en) 2018-02-28
NO2887943T3 (es) 2018-05-05
AU2013267301B2 (en) 2018-02-08
EP2854849A1 (en) 2015-04-08
CO7151478A2 (es) 2014-12-29
MX2014014363A (es) 2015-02-05
MA37645B1 (fr) 2018-10-31
PH12014502429A1 (en) 2015-01-12
NZ702288A (en) 2016-12-23
BR112014028997A2 (pt) 2017-07-25
CN104349791A (zh) 2015-02-11
MA37645A2 (fr) 2016-08-31
US20130323260A1 (en) 2013-12-05
LT2854849T (lt) 2018-05-10
EA201492186A1 (ru) 2015-08-31
TWI609696B (zh) 2018-01-01
CA2872275A1 (en) 2013-12-05
US9675692B2 (en) 2017-06-13
WO2013181486A1 (en) 2013-12-05
JP2015520173A (ja) 2015-07-16
EA029779B1 (ru) 2018-05-31
JP6144758B2 (ja) 2017-06-07
MA37645A3 (fr) 2017-07-31
PT2854849T (pt) 2018-05-09
MX357146B (es) 2018-06-28
IL235468A0 (en) 2014-12-31
SG11201407171XA (en) 2014-11-27
CA2872275C (en) 2021-05-18
TW201400130A (zh) 2014-01-01
UY34842A (es) 2013-12-31
PH12014502429B1 (en) 2015-01-12
KR20150033615A (ko) 2015-04-01

Similar Documents

Publication Publication Date Title
AR092325A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
NZ630885A (en) Antibody formulation
PE20141151A1 (es) Proteinas de union al antigeno cd27l
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20091261A1 (es) Anticuerpos anti-hepcidina
NZ731735A (en) Anti-pd-1 antibodies and methods of use thereof
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
NZ719036A (en) Anti-pdl1 antibody formulations
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20141706A1 (es) Anticuerpos de union a trombina y usos del mismo
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo

Legal Events

Date Code Title Description
FB Suspension of granting procedure